A groundbreaking treatment that delivers a drug directly to the brain may offer hope to restore damaged brain cells in Parkinson’s disease.
Browsing: Parkinson’s disease
We had the pleasure of filming a joint seminar from the Michael J Fox Foundation and Abcam on biomarkers of neuroinflammation in Parkinson’s disease. Discover more about this in our video, with timepoints for each slide included.
Voyager Therapeutics has announced the first patient dosed in RESTORE-1, a Phase II trial of VY-AADC gene therapy for the treatment of Parkinson’s disease.
Gene therapy for disorders such as amyotrophic lateral sclerosis, Parkinson’s disease and Batten disease has seen success in animal models.
Largest study of its kind reveals that the appendix could act as a reservoir for disease-associated proteins related to Parkinson’s disease.
Couldn’t attend the 143rd Annual Meeting of the American Neurological Association? Discover more about the key highlights here.
Chinese tech firm Tencent and British healthcare technology company Medopad are joining forces to develop an artificial intelligence model with the ability to assess motor function in patients with Parkinson’s disease.
In this week’s round-up, we cover the latest industry news from the US FDA and the halt of an Alzheimer’s drug following a toxic reaction.
Results from the Phase III TOLEDO study suggests that treatment of Parkinson’s with apomorphine increases periods of good motor control and reduces periods when Parkinson’s disease medications are ineffective.
Dopamine agonists and prodrugs taken to treat Parkinson’s disease may cause impulse control disorders in over half the patients they are prescribed to.